220 related articles for article (PubMed ID: 15153333)
1. Dynamic contrast-enhanced magnetic resonance imaging rapidly indicates vessel regression in human squamous cell carcinomas grown in nude mice caused by VEGF receptor 2 blockade with DC101.
Kiessling F; Farhan N; Lichy MP; Vosseler S; Heilmann M; Krix M; Bohlen P; Miller DW; Mueller MM; Semmler W; Fusenig NE; Delorme S
Neoplasia; 2004; 6(3):213-23. PubMed ID: 15153333
[TBL] [Abstract][Full Text] [Related]
2. Sensitive noninvasive monitoring of tumor perfusion during antiangiogenic therapy by intermittent bolus-contrast power Doppler sonography.
Krix M; Kiessling F; Vosseler S; Farhan N; Mueller MM; Bohlen P; Fusenig NE; Delorme S
Cancer Res; 2003 Dec; 63(23):8264-70. PubMed ID: 14678984
[TBL] [Abstract][Full Text] [Related]
3. Assessment of vascular remodeling under antiangiogenic therapy using DCE-MRI and vessel size imaging.
Zwick S; Strecker R; Kiselev V; Gall P; Huppert J; Palmowski M; Lederle W; Woenne EC; Hengerer A; Taupitz M; Semmler W; Kiessling F
J Magn Reson Imaging; 2009 May; 29(5):1125-33. PubMed ID: 19388117
[TBL] [Abstract][Full Text] [Related]
4. Rapid vessel regression, protease inhibition, and stromal normalization upon short-term vascular endothelial growth factor receptor 2 inhibition in skin carcinoma heterotransplants.
Miller DW; Vosseler S; Mirancea N; Hicklin DJ; Bohlen P; Völcker HE; Holz FG; Fusenig NE
Am J Pathol; 2005 Nov; 167(5):1389-403. PubMed ID: 16251423
[TBL] [Abstract][Full Text] [Related]
5. Dynamic T1-weighted monitoring of vascularization in human carcinoma heterotransplants by magnetic resonance imaging.
Kiessling F; Heilmann M; Vosseler S; Lichy M; Krix M; Fink C; Kiessling I; Steinbauer H; Schad L; Fusenig NE; Delorme S
Int J Cancer; 2003 Mar; 104(1):113-20. PubMed ID: 12532427
[TBL] [Abstract][Full Text] [Related]
6. Roles of nitric oxide synthase inhibition and vascular endothelial growth factor receptor-2 inhibition on vascular morphology and function in an in vivo model of pancreatic cancer.
Camp ER; Yang A; Liu W; Fan F; Somcio R; Hicklin DJ; Ellis LM
Clin Cancer Res; 2006 Apr; 12(8):2628-33. PubMed ID: 16638876
[TBL] [Abstract][Full Text] [Related]
7. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production.
Sweeney P; Karashima T; Kim SJ; Kedar D; Mian B; Huang S; Baker C; Fan Z; Hicklin DJ; Pettaway CA; Dinney CP
Clin Cancer Res; 2002 Aug; 8(8):2714-24. PubMed ID: 12171905
[TBL] [Abstract][Full Text] [Related]
8. Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts.
Davis DW; Inoue K; Dinney CP; Hicklin DJ; Abbruzzese JL; McConkey DJ
Cancer Res; 2004 Jul; 64(13):4601-10. PubMed ID: 15231672
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of tumor microvascular response to brivanib by dynamic contrast-enhanced 7-T MRI in an orthotopic xenograft model of hepatocellular carcinoma.
Song KD; Choi D; Lee JH; Im GH; Yang J; Kim JH; Lee WJ
AJR Am J Roentgenol; 2014 Jun; 202(6):W559-66. PubMed ID: 24848850
[TBL] [Abstract][Full Text] [Related]
10. Detecting vascular changes in tumour xenografts using micro-ultrasound and micro-ct following treatment with VEGFR-2 blocking antibodies.
Cheung AM; Brown AS; Cucevic V; Roy M; Needles A; Yang V; Hicklin DJ; Kerbel RS; Foster FS
Ultrasound Med Biol; 2007 Aug; 33(8):1259-68. PubMed ID: 17467156
[TBL] [Abstract][Full Text] [Related]
11. Angiogenesis inhibition by vascular endothelial growth factor receptor-2 blockade reduces stromal matrix metalloproteinase expression, normalizes stromal tissue, and reverts epithelial tumor phenotype in surface heterotransplants.
Vosseler S; Mirancea N; Bohlen P; Mueller MM; Fusenig NE
Cancer Res; 2005 Feb; 65(4):1294-305. PubMed ID: 15735015
[TBL] [Abstract][Full Text] [Related]
12. Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma.
Marzola P; Degrassi A; Calderan L; Farace P; Nicolato E; Crescimanno C; Sandri M; Giusti A; Pesenti E; Terron A; Sbarbati A; Osculati F
Clin Cancer Res; 2005 Aug; 11(16):5827-32. PubMed ID: 16115922
[TBL] [Abstract][Full Text] [Related]
13. Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel.
Inoue K; Slaton JW; Davis DW; Hicklin DJ; McConkey DJ; Karashima T; Radinsky R; Dinney CP
Clin Cancer Res; 2000 Jul; 6(7):2635-43. PubMed ID: 10914704
[TBL] [Abstract][Full Text] [Related]
14. Integrin αvβ3-targeted dynamic contrast-enhanced magnetic resonance imaging using a gadolinium-loaded polyethylene gycol-dendrimer-cyclic RGD conjugate to evaluate tumor angiogenesis and to assess early antiangiogenic treatment response in a mouse xenograft tumor model.
Chen WT; Shih TT; Chen RC; Tu SY; Hsieh WY; Yang PC
Mol Imaging; 2012; 11(4):286-300. PubMed ID: 22954145
[TBL] [Abstract][Full Text] [Related]
15. Human tumor xenografts recurring after radiotherapy are more sensitive to anti-vascular endothelial growth factor receptor-2 treatment than treatment-naive tumors.
Kozin SV; Winkler F; Garkavtsev I; Hicklin DJ; Jain RK; Boucher Y
Cancer Res; 2007 Jun; 67(11):5076-82. PubMed ID: 17545583
[TBL] [Abstract][Full Text] [Related]
16. Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice.
Bruns CJ; Shrader M; Harbison MT; Portera C; Solorzano CC; Jauch KW; Hicklin DJ; Radinsky R; Ellis LM
Int J Cancer; 2002 Nov; 102(2):101-8. PubMed ID: 12385004
[TBL] [Abstract][Full Text] [Related]
17. Angiogenesis and radiation response modulation after vascular endothelial growth factor receptor-2 (VEGFR2) blockade.
Li J; Huang S; Armstrong EA; Fowler JF; Harari PM
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1477-85. PubMed ID: 16029810
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin.
Lamszus K; Brockmann MA; Eckerich C; Bohlen P; May C; Mangold U; Fillbrandt R; Westphal M
Clin Cancer Res; 2005 Jul; 11(13):4934-40. PubMed ID: 16000592
[TBL] [Abstract][Full Text] [Related]
19. Preclinical evaluation of tumor microvascular response to a novel antiangiogenic/antitumor agent RO0281501 by dynamic contrast-enhanced MRI at 1.5 T.
Muruganandham M; Lupu M; Dyke JP; Matei C; Linn M; Packman K; Kolinsky K; Higgins B; Koutcher JA
Mol Cancer Ther; 2006 Aug; 5(8):1950-7. PubMed ID: 16928815
[TBL] [Abstract][Full Text] [Related]
20. Monitoring the effects of anti-angiogenesis on the radiation sensitivity of pancreatic cancer xenografts using dynamic contrast-enhanced computed tomography.
Cao N; Cao M; Chin-Sinex H; Mendonca M; Ko SC; Stantz KM
Int J Radiat Oncol Biol Phys; 2014 Feb; 88(2):412-8. PubMed ID: 24411612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
